WO2004074428A3 - Treatment of metabolic disorders - Google Patents

Treatment of metabolic disorders Download PDF

Info

Publication number
WO2004074428A3
WO2004074428A3 PCT/DK2004/000110 DK2004000110W WO2004074428A3 WO 2004074428 A3 WO2004074428 A3 WO 2004074428A3 DK 2004000110 W DK2004000110 W DK 2004000110W WO 2004074428 A3 WO2004074428 A3 WO 2004074428A3
Authority
WO
WIPO (PCT)
Prior art keywords
metabolic disorders
relates
methods
treatment
compounds
Prior art date
Application number
PCT/DK2004/000110
Other languages
French (fr)
Other versions
WO2004074428A2 (en
Inventor
Louise Ambye
Mogens Fenger
Original Assignee
Hvidovre Hospital
Louise Ambye
Mogens Fenger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hvidovre Hospital, Louise Ambye, Mogens Fenger filed Critical Hvidovre Hospital
Publication of WO2004074428A2 publication Critical patent/WO2004074428A2/en
Publication of WO2004074428A3 publication Critical patent/WO2004074428A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to methods for the treatment of metabolic disorders, including diabetes mellitus type 2, associated with mutations/polymorphisms in the promoter region of muscle glycogen synthase. The invention comprises the use of compounds to raise the level of activity of muscle glycogen synthase, either by increasing gene expression or by directly or indirectly increasing the enzyme activity. Furthermore, the invention relates to gene therapy methods and to constructs for use in these. The invention also relates to methods, vectors and host cells for screening for compounds for activity against metabolic disorders of the type described.
PCT/DK2004/000110 2003-02-21 2004-02-19 Treatment of metabolic disorders WO2004074428A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200300272 2003-02-21
DKPA200300272 2003-02-21
US44943403P 2003-02-25 2003-02-25
US60/449,434 2003-02-25

Publications (2)

Publication Number Publication Date
WO2004074428A2 WO2004074428A2 (en) 2004-09-02
WO2004074428A3 true WO2004074428A3 (en) 2004-11-25

Family

ID=32910025

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2004/000110 WO2004074428A2 (en) 2003-02-21 2004-02-19 Treatment of metabolic disorders

Country Status (1)

Country Link
WO (1) WO2004074428A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108271740B (en) * 2018-01-23 2020-01-17 新乡医学院 Method for establishing neutrophilic granulocyte-deficient atherosclerosis model mouse

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0846763A2 (en) * 1996-12-05 1998-06-10 Smithkline Beecham Corporation A protein phosphatase 1 binding protein, R5
WO2001052862A1 (en) * 2000-01-19 2001-07-26 Isis Pharmaceuticals, Inc. Antisense modulation of glycogen synthase kinase 3 beta expression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0846763A2 (en) * 1996-12-05 1998-06-10 Smithkline Beecham Corporation A protein phosphatase 1 binding protein, R5
WO2001052862A1 (en) * 2000-01-19 2001-07-26 Isis Pharmaceuticals, Inc. Antisense modulation of glycogen synthase kinase 3 beta expression

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BJORBAEK C ET AL: "GENETIC VARIANTS IN PROMOTERS AND CODING REGIONS OF THE MUSCLE GLYCOGEN SYNTHASE AND THE INSULIN-RESPONSIVE GLUT4 GENES IN NIDDM", DIABETES, NEW YORK, NY, US, vol. 43, August 1994 (1994-08-01), pages 976 - 983, XP002925298, ISSN: 0012-1797 *
HENRIKSEN ERIK J ET AL: "Glycogen synthase kinase-3 (GSK3) inhibitors potentiate glucose tolerance and muscle glycogen synthase activity and glucose uptake in the Zucker diabetic fatty (ZDF) rat", DIABETES, vol. 50, no. Supplement 2, June 2001 (2001-06-01), & 61ST SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION; PHILADELPHIA, PENNSYLVANIA, USA; JUNE 22-26, 2001, pages A279, XP008035843, ISSN: 0012-1797 *
ORHO M ET AL: "ISOLATION AND CHARACTERIZATION OF THE HUMAN MUSCLE GLYCOGEN SYNTHASE GENE", DIABETES, NEW YORK, NY, US, vol. 44, no. 9, September 1995 (1995-09-01), pages 1099 - 1105, XP008031754, ISSN: 0012-1797 *
ST-ONGE J ET AL: "The stimulation-induced increase in skeletal muscle glycogen synthase content is impaired in carriers of the glycogen synthase XbaI gene polymorphism", DIABETES, NEW YORK, NY, US, vol. 50, no. 1, January 2001 (2001-01-01), pages 195 - 198, XP002284407, ISSN: 0012-1797 *

Also Published As

Publication number Publication date
WO2004074428A2 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
Tanaka Antiaging effects of aerobic exercise on systemic arteries
WO2003038123A3 (en) Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene
WO2004092405A3 (en) Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof
MX2007015848A (en) Genetic variants in the tcf7l2 gene as diagnostic markers for risk of type 2 diabetes mellitus.
WO2006065582A3 (en) Muteins of fibroblast growth factor 21
WO2005077072A3 (en) Hybrid polypeptides with selectable properties
WO2007022123A3 (en) Hybrid polypeptides with selectable properties
WO2009042435A8 (en) Pyridin-2 -yl-amino-i, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
WO2004048526A3 (en) MODULATION OF HIF1α AND HIF2α EXPRESSION
WO2005112619A3 (en) Novel gene disruptions, compositions and methods relating thereto
SG161247A1 (en) Variant forms of urate oxidase and use thereof
WO2006031955A3 (en) Method for treatment with bucindolol based on genetic targeting
WO2004101752A3 (en) Compounds for treatment of inflammation, diabetes and related disorders
WO2005118538A3 (en) Arylsulfonamides and uses as hydroxysteroid dehydrogenase
WO2008157787A3 (en) Hydroxylated tolans and related compounds in the treatment of cancer
WO2004009024A3 (en) Modulation of protein kinase c-iota expression
WO2003085093A3 (en) Antibodies that specifically bind to gmad
WO2006076695A3 (en) Genetic screening for improving treatment of patients diagnosed with depression
WO2006063703A8 (en) Single nucleotide polymorphism (snp) associated to type ii diabetes
WO2007070355A3 (en) Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
WO2004018633A3 (en) Abca13 nucleic acids and proteins, and uses thereof
WO2005062958A3 (en) Meth0ds of using hcn genes to treat cardiac arrhythmias
WO2009058970A3 (en) A novel gene therapy approach for treating the metabolic disorder obesity
WO2004074428A3 (en) Treatment of metabolic disorders
WO2005062957A3 (en) Compositions and methods for combined therapy of disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase